Press Release
23 February 2026 17:10:00 CET

Invitation to presentation including Q&A session of Qlucore's interim report for the period 1 May 2025 – 31 January 2026

Qlucore's interim report for the period 1 May 2025 – 31 January 2026 will be published 26 February 2026.

Qlucore invites you to a video conference where the interim report will be presented by the CEO. There will be a Q&A session after the presentation. The presentation will be in Swedish. Questions can be asked in English.

Date: Thursday 26th of February at 10.30 am CET.

Meeting link (Teams): Connect

Certified Advisor

FNCA Sweden AB
Web: **www.fnca.se**

Contacts

Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 10
Email: **carl-johan.ivarsson@qlucore.com**

About Qlucore

Qlucore develops AI#based software that enables more accurate diagnostics and a more cost#efficient healthcare system. Through the company's precision medicine solutions, tens of thousands of genetic data points are transformed into clear decision#making support, making it possible to deliver the right treatment to each patient at the right time.

The first diagnostic test – for pediatric blood cancer – has been approved for sale within the EU. Additional tests, including for lung cancer, adult blood cancer, and bladder cancer, are under development. These products target large and growing markets with significant medical and economic needs. The goal is to improve treatment outcomes, reduce human suffering, and lower healthcare costs.

In addition to its diagnostics portfolio, Qlucore offers Qlucore Omics Explorer, an established software platform for advanced data analysis used by researchers and pharmaceutical companies worldwide. The company has customers in about 20 countries, sales offices in Europe and North America, and distributors across several Asian markets.

Qlucore is listed on Nasdaq First North Growth market. More information: **www.qlucore. com**

Attachments

Invitation to presentation including Q&A session of Qlucore's interim report for the period 1 May 2025 – 31 January 2026